Testing a new treatment strategy for lupus to prevent damage

Plain-English translation of NCT05714930 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a new approach to treating lupus called 'treat-to-target,' which aims to reach and maintain complete disease remission (meaning no active disease and low steroid doses). Half of the participating clinics will use this intensive, guided approach with frequent check-ins and medication adjustments, while the other half will continue with standard care. The study will follow about 600 patients for about 2 years to see if this targeted strategy prevents long-term damage and helps people feel better.

Many people with lupus experience ongoing disease activity that leads to permanent organ damage over time, even with treatment. This trial is testing whether aiming for complete disease control — and adjusting medications more aggressively to reach that goal — can prevent that damage and improve patients' quality of life better than the current standard approach.

Do you qualify?

You likely qualify if…

you have been diagnosed with systemic lupus erythematosus using standard medical criteria
you are 18 years of age or older
your lupus is not currently in full remission (meaning you still have some disease activity, need higher steroid doses, or show signs of active disease)
you are fluent in German
you are willing to provide written informed consent to participate

You likely don't qualify if…

you have a life-threatening lupus complication requiring intensive hospital care
you have another serious active infection or disease that would make intensifying lupus medication unsafe
you have been diagnosed with an active cancer
you are currently enrolled in another research study testing a new treatment
you have a medical condition that, in your doctor's judgment, would make participation unsafe or difficult

What participation looks like

If you are assigned to the new treatment strategy, you will visit the clinic every 6 weeks for up to 24 weeks while your medications are adjusted to reach complete disease control. Once you reach that target, visits drop to every 12 weeks. If your disease flares, you return to closer monitoring. If you are assigned to standard care, you will have check-ins every 3 to 6 months as usual. The entire study lasts about 2 years, and doctors will measure changes in your disease activity, medication needs, and quality of life throughout.

AI-generated summary from trial data · Jun 20, 2026 · Not medical advice

Trial locations(14 sites)

Germany

University Clinic Freiburg, Freiburg im Breisgau, Baden-Wurttemberg

University Clinic Heidelberg, Heidelberg, Baden-Wurttemberg

University Clinic Erlangen, Erlangen, Bavaria

LMU Munich, Munich, Bavaria

University Clinic Frankfurt, Frankfurt am Main, Hesse